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ABSTRACT
Podocytes possess the complete machinery for glutamatergic signaling, raising the possibility that
neuron-like signaling contributes to glomerular function. To test this, we studied mice and cells lacking
Rab3A, a small GTPase that regulates glutamate exocytosis. In addition, we blocked the glutamate
ionotropic N-methyl-D-aspartate receptor (NMDAR) with specific antagonists. In mice, the absence of
Rab3A and blockade of NMDAR both associated with an increased urinary albumin/creatinine ratio. In
humans, NMDAR blockade, obtained by addition of ketamine to general anesthesia, also had an
albuminuric effect. In vitro, Rab3A-null podocytes displayed a dysregulated release of glutamate with
higher rates of spontaneous exocytosis, explained by a reduction in Rab3A effectors resulting in freedom
of vesicles from the actin cytoskeleton. In addition, NMDAR antagonism led to profound cytoskeletal
remodeling and redistribution of nephrin in cultured podocytes; the addition of the agonist NMDA
reversed these changes. In summary, these results suggest that glutamatergic signaling driven by
podocytes contributes to the integrity of the glomerular filtration barrier and that derangements in this
signaling may lead to proteinuric renal diseases.
J Am Soc Nephrol 20: 1929–1940, 2009. doi: 10.1681/ASN.2008121286
It is widely recognized that most glomerular dis-
eases are characterized by defects of the filtration
barrier, where podocytes play a central role. Muta-
tions of single podocyte proteins have been found at
the basis of human nephrotic syndromes,1 and
podocyte deletion of the same molecules causes
heavy proteinuria in experimental models.2–8
Podocytes are highly ramified cells: From the cell
body depart a number of primary processes, further
originating secondary foot processes. Starting from
these features, it has been demonstrated that podo-
cytes share numerous similarities with neurons:
They both are terminally differentiated cells, have a
common cytoskeletal organization, and have a
common machinery of process formation.9 Fur-
thermore, a number of expression-restricted pro-
teins, such as nephrin,2 Neph1 and Neph2,10
GLEPP1,11 CAT3 and EAAT2,12 synaptopodin,13
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drebrin,14 and Sam68-like-MP2,15 specifically belong to the
podocyte and the neuron.
Our group has contributed to this line of research, initially
by describing in podocytes the presence of Rab3A, a small
GTPase that is mostly enriched in synaptic vesicles because it
tightly modulates highly regulated exocytosis by acting
through a number of effector molecules, including rabphi-
lin-3a and Synapsin-I.16 After finding that in podocytes, as it
occurs in neurons, Rab3A associates to glutamate-containing
vesicles along cell processes, we discovered that podocytes are
equipped with a complete neuron-like glutamatergic signaling
system.17 We described that podocytes possess functional syn-
aptic-like microvesicles and renal glomeruli express cognate
glutamate transporters and receptors. These properties
strengthened the analogies between podocytes and neurons
and offered a rational interpretation to the biochemical simi-
larity of foot process and synaptic adhesion complexes17; how-
ever, the role played by glutamate signaling
in podocytes remained unanswered, and
nothing was known about its relevance to
podocyte and glomerular homeostasis. To
get more details on the requirement of this
neuron-like system of signaling by podo-
cytes, we first conducted a preliminary
analysis on its temporal appearance during
podocyte differentiation. Then we studied
conditions in which it was altered, on the
vesicle and on the receptor side. The vesic-
ular component was analyzed by studying
the consequences of the absence of Rab3A.
On the receptor side, we antagonized the
ionotropic N-methyl-D-aspartate receptor
(NMDAR), that we found present in hu-
man and rodent glomeruli, as well as in
podocyte cell cultures.17 Both Rab3A and
NMDAR1 glomerular synthesis were also
confirmed by in situ hybridization (Supple-
mental Figure 1) and bymicroarray expres-
sion data.17
RESULTS
Glutamate Release Is a Property of
Mature Podocytes
We first looked at the expression of Rab3A,
a marker of mature synapses,18 and its ef-
fector rabphilin-3A in developing glomer-
uli of newborn mice. Different from other
podocyte molecules, such as nephrin and
synaptopodin, which are fully expressed by
day 1 after birth, Rab3A and rabphilin-3A
were still negative in developing glomeruli
of 1-d-old mice and appeared subse-
quently, mainly by day 30, in mature glo-
meruli (Figure 1A), where podocyte locationwas confirmed by
podocin co-labeling (Supplemental Figure 2).
These data suggested Rab3A and rabphilin-3A are part of a
system needed by mature glomeruli; therefore, we analyzed
glutamate release during podocyte differentiation by using a
conditionally immortalized podocyte cell line,19 derived from
theH-2Kb-tsA58 transgenic mouse, in which the SV40 large T
antigen is both temperature and -IFN dependent.
In neurons, spontaneous release typically occurs with a rate
of one to two vesicles per minute per release site,20 whereas
evoked release occurs at a rate of100 vesicles/s.21 We evoked
stimulated exocytosis by -latrotoxin (-LTX), a presynaptic
neurotoxin widely used to trigger synaptic vesicles exocyto-
sis.22
Undifferentiated podocytes, maintained at 33°C with
-IFN, are proliferating cells that never exhibit a podocyte phe-
notype. In up to 40-min observation, these cells did not show
Figure 1. Glutamate exocytosis is a property of mature podocytes. (A) Developmen-
tal appearance of Rab3A and Rabphilin-3A. Compared with nephrin and synaptopo-
din, expressed in developing glomerular capillaries in newborn mice, Rab3A and
rabphilin-3A stainings are completely negative (top, 1-d-old mouse). Both Rab3A and
rabphilin-3A are positive in completely mature glomerular structures of a 30-d-old
mouse (bottom). Indirect immunofluorescence: nephrin, bar 100 m; synaptopodin,
Rab3A, and rabphilin-3A, bar  50 m; bottom, bar  50 m. (B) Glutamate exocy-
tosis during podocyte differentiation. Glutamate was measured in the culture super-
natant as expression of NADH generation at the beginning of the experiment (0) and
every 10 min up to 40 min (time points on the x axis). Data come from three different
sets of experiments, and results are expressed as percentage variation from the
baseline (y axis, mean SD). (a) Spontaneous () and -LTX–stimulated (f) glutamate
exocytosis do not take place in undifferentiated podocytes grown at 33C in presence
of -IFN (see the Concise Methods section). (b) Differentiated podocytes display
spontaneous () glutamate release at 40 min. Nanomolar -LTX addition causes
glutamate release at increasing concentrations (f). As it occurs in neuronal cells,20,21
regulated exocytosis is greater than spontaneous glutamate release (*P  0.05; **P 
0.01). Magnifications: 200 in A, top, nephrin; 630 in A, top, synaptopodin, Rab3A,
and rabphilin-3A; 400 in A, bottom.
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any glutamate release, either spontaneous
or stimulated (Figure 1B, a).
By growing 15 d at 37°C without -IFN,
cells stop to divide and differentiate to a
mature podocyte phenotype. Their rate of
spontaneous glutamate release was very
mild and not measurable until 40 min. Ad-
dition of -LTX elicited an outburst of glu-
tamate, measurable at 10 min and progres-
sively increasing (Figure 1B, b).
Rab3A-Knockout Model
Then we analyzed the possible appearance
of a renal phenotype in Rab3A-null mice.
Actually, Rab3A absence from podocytes
became symptomatic by 3 mo of age, when
Rab3A-knockout (KO) mice displayed
macroalbuminuria (albuminuria/creat-
ininuria ratio [UAlb/UCreat] 302 38g/
mg; mean  SD) that persisted over time,
whereas lower values were detectable in
wild-type (WT)mice (UAlb/UCreat 157
33 g/mg; P 0.03; Figure 2A).
KO and WT 3-mo-old kidneys did not
show abnormalities by light microscopy
(Figure 2B, a and b, e and f), whereas trans-
mission electronmicroscopy demonstrated
segmental areas of podocyte foot process
effacement in KO glomeruli (Figure 2B, c;
Supplemental Figure 3). By scanning elec-
tron microscopy, KO podocytes showed a
disorganized, less ordered foot process
structure (Figure 2B, d) thanWT cells (Fig-
ure 2B, h). Focal and segmental decrease of
podocyte proteins was detectable by immu-
nofluorescence in KO glomeruli (Supple-
mental Figure 4, A through F) but was not
accompanied by reduction of podocyte
number (Supplemental Figure 4G). Over-
all, podocyte changes in Rab3A-KO mice
offered a morphologic support to the evi-
dence of macroalbuminuria; therefore, to understand the con-
sequences of Rab3A absence in podocytes, we compared glu-
tamate exocytosis in primary podocytes from Rab3A-WT and
KO animals.
A mild spontaneous release of glutamate from WT podo-
cytes becamedetectable only after 40min, andnanomolar con-
centrations of -LTX (2.5 nM) caused a glutamate release
measurable at 10 min and increasing with time (Figure 3A, a).
Instead, KOpodocytes demonstrated a spontaneous glutamate
release already detectable at 10 min and gradually decreasing
with time, but they did not show any response after -LTX
application (Figure 3A, b).
These results were confirmed by experiments in which re-
cycling vesicles were monitored by the styryl dye FM1-43.
Styryl dyes reversibly insert into the surface of lipid mem-
branes and have no fluorescence properties in aqueous solu-
tion but become intensely fluorescent on membrane binding,
allowing labeling of recycling vesicles that is detectable by flu-
orescence microscopy. In 20-min observation, WT podocytes
did not become fluorescent when the dye was added alone,
whereas a bright fluorescence signal appeared after -LTX ad-
dition. Different fromWT cells, KO podocytes became imme-
diately fluorescent after addition of the dye, but the subsequent
addition of -LTX did not produce changes in cell fluores-
cence (Figure 3B).
To analyze further the different behavior of WT and KO
podocytes, we studied the expression of Rab3A effectors rab-
philin-3A and Synapsin-I. Rab3A exerts its role by switching
Figure 2. The renal phenotype of Rab3A-KO mice. (A) Macroalbuminuria is present
in Rab3A-KO mice. UAlb/UCreat (g/mg) was measured on 24-h urine samples in 27
Rab3A WT () and 27 KO animals (f). Data are means  SD. Rab3A-WT (nine animals
per age group, mean  SD) show microalbuminuria, as expected according to the
strain: 3m  157  33 g/mg; 6m  160  23 g/mg; 9m  150  29 g/mg.
Rab3A-KO (nine animals per age group, mean SD) display steady macroalbuminuria
over time: 3m  302  38 g/mg; 6m  322  59 g/mg; 9m  325  46 g/mg.
*KO versus WT: P  0.03. (B) Three-month-old Rab3A-KO and WT mice: Morphologic
renal features. By light microscopy (KO: a and b; WT: e and f) kidneys display normal
morphologic features (a and e: bars  100 m; b and f: bars  50 m). A glomerulus
from a KO animal, observed by transmission electron microscopy (c; bar  2 m),
shows segmental foot process effacement (arrows), whereas a glomerulus from a
corresponding WT animal has normal foot processes (g; bar  5 m). Scanning
electron microscopy allows the observation of disorganized podocyte foot process ar-
rangement in a KO mouse (d; bar  1 m) and of the ordered structure of processes in a
WT animal (h; bar 1 m). Magnifications:100 in B, a and e;400 in B, b and f;6000
in B, c and g; 20000 in B, d and h.
BASIC RESEARCHwww.jasn.org
J Am Soc Nephrol 20: 1929–1940, 2009 Neuron-Like Podocyte Signaling 1931
between a GDP-cytosolic form to a GTP vesicle–linked form,
which interacts with multiple effectors. When GTP-Rab3A re-
cruits rabphilin-3A and Synapsin-I, they control vesicle motil-
ity by regulating vesicle-actin association. Rabphilin-3A ac-
complishes this task by interacting with -actinin,23 and
Synapsin-I acts by switching between a phosphorylated and a
dephosphorylated form, respectively releasing or anchoring
vesicles to actin.24
Compared with WT cells, Rab3A-KO podocytes displayed
decreased expression of both effectors (Figure 4, A throughC),
but despite total Synapsin-I reduction, KO podocytes had
more phosphorylated Synapsin-I than WT cells (Figure 4D).
Figure 3. Differences in the pattern of glutamate exocytosis by
WT and KO podocytes. (A) Glutamate exocytosis in primary
podocytes from WT and KO mice. Glutamate was measured in
the culture supernatant as expression of NADH generation at the
beginning of the experiment (0) and every 10 min up to 40 min
(time points on the x axis). Data come from three different sets of
experiments, and results are expressed as percentage variation
from the baseline (y axis, mean SD). (a) Spontaneous exocytosis
in Rab3A-WT podocytes () is measurable at 40 min. Addition of
-LTX (f) produces glutamate exocytosis measurable at 10 min
and increasing over time. (b) Rab3A-KO podocytes spontane-
ously demonstrate glutamate release () at 10 min but do not
show any exocytosis when stimulated by -LTX (f). (B) Vesicle
recycling. WT and KO podocytes are loaded with the styryl dye
FM1-43 at the beginning of the experiment, and vesicle recycling
is followed by live microscopy. WT cells (top) do not take up the
dye in 20-min observation. After addition of -LTX, cells become
and remain fluorescent. The dye instead spontaneously inserts on
the membrane of KO cells (bottom), and fluorescence does not
change with the addition of -LTX. Bars 100 m. Magnification,
200.
Figure 4. Rab3A effector molecules. (A through D) Rab3A effec-
tor molecules in cultured podocytes. Compared with WT cells (A),
that along Rab3A express rabphilin-3A and Synapsin-I, KO podo-
cytes (B) look negative for Rab3A and show a decreased expres-
sion of both the effectors rabphilin-3A and Synapsin-I. Indirect
immunofluorescence, bars  50 m. (C and D) Western Blot
analysis confirms the presence of Rab3A only in WT podocytes
and the reduction of rabphilin-3A and Synapsin-I in KO podo-
cytes. (D) Phosphorylated Synapsin-I is instead lower in WT than
in KO cells. (E and F) Rab3A effector molecules in mouse glomer-
uli. WT glomeruli (E) express Rab3A and its effectors, whereas the
absence of Rab3A in a KO mouse (F) is accompanied by reduced
expression of rabphilin-3A and Synapsin-I. Indirect immunofluo-
rescence, bars  50 m. Magnification, 400.
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Rabphilin-3A and Synapsin-I downregulation were confirmed
by immunofluorescence in KO glomeruli (Figure 4, E and F),
and higher expression of phospho-Synapsin-I was confirmed
in KO animals by immunogold electron microscopy (Supple-
mental Figure 5).
NMDAR Blockade as a Model of Receptor Alteration
To block the NMDAR, we alternatively used norketamine hy-
drochloride or dizocilpinemaleate (MK-801), which are selec-
tive, noncompetitive antagonists that act by binding to the
phencyclidine binding site located within the ion channel,
thereby preventing Ca2 flux. We first applied the antagonists
on cultured cells, namely primary podocytes from Balb/c mice
and the differentiated podocyte cell line.
Either norketamine or MK-801, applied for 30 min at the
concentration of 50 and 10 M, respectively, was sufficient
to cause a profound remodeling of podocyte cytoskeleton,
as evidenced by almost complete disappearance of actin
stress fibers and myosin-IIA redistribution (Figure 5A, a, b,
d, and e). These changes were accompanied by disappear-
ance of nephrin from podocyte processes (Figure 5A, g and h)
and, similar to neuronal cells,25 by an increased expression of
NMDAR1(Figure5B).Wewereable almost tocompletely reverse
cytoskeletal remodeling andnephrin redistributionwhen incuba-
tion with norketamine was followed by addition of the agonist
NMDA, applied at a concentration of 50 M for 15 min (Figure
5A, c, f, and i).
NMDAR is a calcium channel tightly linked to the actin
cytoskeleton. At the synapse, NMDAR activation leads to in-
tracellular calcium rise that activates calmodulin-dependent
protein kinase II (CaMKII) by phosphorylation. In turn, phos-
pho-CaMKII phosphorylates a series of downstream mole-
Figure 5. NMDAR in vitro blockade. (A) Effects on the cytoskeleton and nephrin expression. (a, b, d, e, g, and h) Compared with
cells incubated with medium (a, d, and g), application of the NMDAR antagonist norketamine hydrochloride produces remodeling
of the actin (b) and myosin IIA (e) cytoskeleton and redistribution of nephrin (h), which disappears from cell processes. (c, f, and
i) The addition, after the antagonist, of the agonist NMDA, abolishes almost completely the agonist’s effects. Phalloidin-TRITC (a
through c); indirect immunofluorescence (d through i); bars  50 m. (B) Effects on NMDAR1 expression. (a and b) Compared with
cells incubated with medium (a), addition of norketamine hydrochloride (b) determines an increased expression of the NMDAR1.
Indirect immunofluorescence, bars  50 m. (c) Cells incubated with medium (lanes 1 through 3) express less NMDAR1 (band of
approximately 100 kD) than cells treated by norketamine hydrochloride (lane 4). The lower band of 50 kD represents tubulin
(loading control). (C) Downstream effects of the NMDAR blockade. Compared with cells incubated with medium (a and b, lane 1),
phosphorylated CaMKII (a) and phosphorylated cofilin (b) are reduced, as compared with total CaMKII and total cofilin, after 15
(lane 2) and 30 min (lane 3) of treatment with norketamine hydrochloride. The graphs show a densitometric representation of
Western blot results obtained from three experiments, where the ratio of lane 1 is taken at the arbitrary value of 100.
Magnification, 400.
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cules, including cofilin, thereby regulating actin dynamics.26
Western blot analysis of CaMKII and cofilin in cultured podo-
cytes, after 15 and 30 min of incubation with the NMDAR
antagonist, showed at both time points a reduced CaMKII
phosphorylation and reduced phosphorylation of cofilin (Fig-
ure 5C), likely responsible for actin remodeling.
To establish whether the NMDAR blockade had a direct
effect on glomerular permeability, we measured differences in
convective glomerular albumin permeability (PAlb) on iso-
lated rat glomeruli incubated with either norketamine or
MK801 at various concentrations and time points. Both antag-
onists, particularly at the same concentrations and times used
on cultured cells, were able to increase significantly glomerular
PAlb (Figure 6, A through C). The effect of norketamine was
completely reversed when glomeruli were subsequently incu-
bated with NMDA (50 M for 15 min), whereas only a mild
effect was achieved when NMDA followed the more potent
MK-801 (Figure 6D); therefore, we moved to the in vivo ap-
proach, by intraperitoneal norketamine injection in 16 Balb/c
mice for 3 d at the concentration of 0.3 mg/100 g, which is at
least 20 times less than the anesthetic dosage27 and one 10th the
concentration required to induce psychotic symptoms in ro-
dents.28 Sixteen controlmicewere administered an injection of
saline.
UAlb/UCreat, evaluated on 24-h urine, increased after nor-
ketamine treatment (Figure 7A).Histology did not showmajor
glomerular alterations; however, immunofluorescence dem-
onstrated a globally decreased expression of nephrin (Figure
7B) in treated animals.
Norketamine hydrochloride is the major metabolite of ket-
amine, a general anesthetic optionally included in many rou-
tine protocols. A prospective pilot study was conducted to ver-
ify whether also in humans its application could be related to
UAlb/UCreat differences. According to the inclusion criteria (see
the Concise Methods section), 43 patients were initially en-
rolled. Three patients were excluded because of per-procedure
hemodynamic instability. A final cohort of 40 patients was an-
alyzed. Ketamine and ketamine groups were comparable
in terms of age, body mass index, estimated GFR, baseline
UAlb/UCreat, and mean arterial pressure at H0 (before anesthe-
sia) and H1 (1 h after anesthesia; Table 1). Percentage of celio-
scopic surgery (68% in ketamine versus 71% in ketamine;
P  0.89), use of isoflurane for anesthesia maintenance (33
versus 29%; P  0.99), and aminoglycosides (13 versus 12%;
P  0.89) were comparable as well. Although not reaching
statistical significance (P  0.16), ketamine subjects had
higher H1/H0 of UAlb/UCreat than ketamine, with a median
multiplication factor in UAlb/UCreat between H0 and H1 of 9.0
(4.3 to 15.6) in ketamine and 4.2 (2.7 to 8.8) in ketamine
(Figure 8).
Figure 6. (A and B) Effects of NMDAR blockade on PAlb. Application of growing dosages of norketamine hydrochloride (A) and
MK-801 (B) on isolated glomeruli (see the Concise Methods section) has a dosage-dependent effect on PAlb, compared with the
application of medium alone (Ctrl). (C) The same concentrations used in the in vitro experiments produce effects at different times: 50
M norketamine () changes PAlb when applied for at least 30 min, whereas 10 M of the more potent MK-801 (f) becomes effective
already after 10 min. (D) The addition of the antagonist NMDA at a dosage of 50 M, and applied for 15 min, completely abolishes
norketamine effects, whereas it only mildly reduces the action of MK-801. *P  0.005 versus Ctrl; **P  0.001 versus Ctrl.
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DISCUSSION
Glutamate is themajor excitatory neurotransmitter in the cen-
tral nervous system, and its signaling at synapses has been ex-
tensively studied.29 Meanwhile, evidence gathered during the
past decade has shown the existence of functional glutamate
signaling in several non-neuronal cells, such as osteoblasts,30
pancreatic  islet cells,31 andmegakaryocytes.32 We previously
observed that podocytes are
equippedwith the necessary vesicular
and receptor apparatus to use gluta-
matergic transmission,17 and here we
show that glutamatergic signaling
driven by podocytes seems relevant
to the maintenance of glomerular fil-
ter integrity, because its dysregula-
tion is accompanied by podocyte al-
terations and increased albuminuria.
The question arising is why cells
other than neurons would use gluta-
mate for signaling. As for the glomer-
ulus, we know that the entire blood volume passes the filter
every 5 to 6 min, meaning that the glomerular barrier is con-
stantly exposed to continuous physical (BP) and chemical
(blood content) microenvironmental changes; therefore, ef-
fectiveness in maintaining filter homeostasis highly depends
on efficient intercellular communication. Glutamate perfectly
fits the need because, different from other types of intercellular
communication, it has the advantage of being highly regulated.
Figure 7. NMDAR in vivo blockade. (A) Measurement of albuminuria. (a) Representative results from 3-mo-old animals, intraperito-
neally injected with either saline (lanes 2, 3, 6, and 7) or norketamine hydrochloride (lanes 4 and 5) for 3 d. Twenty-four-hour urine
samples were collected, run on an SDS-PAGE, and silver stained. Albumin bands (molecular weight approximately 60 kD) are increased,
and other bands of lower molecular weight appear in the urine of norketamine-injected animals (lanes 4 and 5). Lane 1 is a negative
control, made by running PBS alone. (b) UAlb/UCreat from urine samples of all animals (mean  SD). Although not statistically significant,
mean UAlb/UCreat is higher in the group injected with norketamine, compared with saline-injected controls. (B) Evaluation of podocyte-
specific proteins. Comparison of podocyte proteins in glomeruli from a saline-injected (left) and a norketamine-injected (right) mouse.
Podocin staining is identical in both samples, whereas a segmental reduction of ZO-1 and a global decrease of nephrin can be noticed
in glomeruli of the norketamine-treated mouse, as compared with the staining of the saline-injected animal. Indirect immunofluores-
cence, bars  50 m. Magnification, 400.
Table 1. Clinical featuresa
Parameter
Ketamine
(n  20)
Ketamine
(n  20)
P
Age (yr) 39 (32 to 50) 42 (32 to 50) 0.95
BMI (kg/m²) 22.5 (20.6 to 26.2) 22.3 (20.5 to 26.2) 0.89
Baseline creatininemia (mol/L) 61.0 (56.8 to 64.2) 59.5 (52.0 to 64.0) 0.86
MDRD eGFR (ml/min per 1.73 m²) 100 (95 to 117) 107 (89 to 125) 0.79
H0 MAP (mmHg) 97 (88 to 103) 93 (80 to 110) 0.37
H1 MAP (mmHg) 83 (73 to 90) 83 (72 to 93) 0.97
H0 UAlb/UCreat (mg/mmol) 0.8 (0.5 to 1.3) 0.7 (0.5 to 1.5) 0.64
aCharacteristics of patients, according to the use of ketamine. Data are median (25th to 75th percentiles).
Values in Ketamine and Ketamine groups are compared by Mann-Whitney U test. eGFR, estimated GFR;
MAP, mean arterial pressure.
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Processes of highly regulated exocytosis involve a complex
interplay among numerous proteins that coordinate vesicle
transport, docking, priming, fusion, and recycling events,most
of them subjected to finemodulation. Amongmodulating fac-
tors, one of the best studied is Rab3A, a versatile catalyst that
tightly controls vesicle release probability.33
In neurons, Rab3A is an important late element in the es-
tablishment of themature characteristics of presynaptic termi-
nals.18 Rab3A is also considered a marker of maturation in
cultured pancreatic rudiments34; therefore, its appearance in
mature glomeruli is coherent with these data and is compatible
with our hypothesis of the usefulness of neuron-like signaling
to cope with postnatal microenvironmental changes. The ab-
sence of glutamate release in undifferentiated podocytes and
its appearance in differentiated cells further prove that a devel-
oped synaptic-like transmission is a property of mature podo-
cytes.
Absence of Rab3A from KO glomeruli manifests itself with
a relatively mild renal phenotype, witnessed by steady mac-
roalbuminuria, which is in keeping with the very mild neuro-
logic phenotype of these animals.35 but, different from neu-
rons, where synapse morphology looks intact,36 podocytes
display alterations detectable by transmission electronmicros-
copy and scanning electronmicroscopy. Immunofluorescence
integrates these findings, showing focal segmental decrease of
podocyte proteins and providing molecular support to the ev-
idence of macroalbuminuria. From these data, we can there-
fore argue that a tight modulation of glutamate exocytosis,
such as the one performed by Rab3A, may be required for the
correct functioning of the filtration barrier.
Our in vitro studies seem to help in understanding the type
of alteration determined by Rab3A absence. Different from
WT cells, Rab3A-KO podocytes display a sustained spontane-
ous exocytosis that impairs correct answers when a stimulus is
applied. Here, previous data on neurotransmitter release by
cells obtained from Rab3A-null mice concordantly show
changes in vesicle transport and fusion, suggesting that Rab3A
plays a role in controlling the number of available vesicles in an
activity-dependent way.37
In KO podocytes, the dysregulated pattern of signaling
could be explained by the concomitant reduction of two
Rab3A effectors: Rabphilin-3A and Synapsin-I. A decreased
rabphilin-3A has been repeatedly documented in Rab3A-KO
mice, and a series of experiments have demonstrated that, in
absence of Rab3A, rabphilin-3A becomes unstable and is de-
graded.38 Here we show that in Rab3A-KO podocytes, there is
also a decrease of Synapsin-I. Both rabphilin-3A and Synap-
sin-I are important regulators of the binding of vesicles to ac-
tin,23,24 and their reduction can likely account for increased
freedom of vesicles to be spontaneously released. Our data on
the relative prevalence of phospho-Synapsin-I in KO cells
points in the same direction, because Synapsin-I phosphoryla-
tion is a precise signal to release vesicles from actin.39
At the synapse, actin is the most prominent cytoskeletal
protein.26 Notably, in both neurons and podocytes, actin is
highly enriched in the tiny projections that depart frommajor
processes, namely dendritic spines and foot processes,9 and
actin dynamics have been proved essential formaintaining and
regulating these specialized compartments.26,40
Our data show profound cytoskeletal changes in podocytes
after in vitro NMDAR blockade. In neuronal cells, NMDARs
are intimately associated with the actin cytoskeleton. Indeed,
actin is directly coupled to theNMDAR via-actinin and spec-
trin.41,42 Interdependence between NMDAR activity and in-
tegrity of the actin cytoskeleton has been demonstrated; influx
of extracellular calcium via NMDAR activation causes stabili-
zation of actin,43 whereas excessive NMDAR activation or
blockade induces actin depolymerization,44 and actin depoly-
merization strongly affects NMDAR activity.45
As for the consensual myosin-IIA redistribution observed
in our experiments, it is known that nonmuscle myosin-IIA is
present in foot processes,40 although few studies have ad-
dressed its role. Myosin-IIA mutations are causative of Fetch-
ner syndrome, whose renal phenotype is characterized by pro-
teinuria and segmental foot process effacement.46 Myosin-IIA
is also expressed postsynaptically by mature neurons, where it
has a role in structural plasticity of excitatory synapses.47 Inter-
estingly, a proteomic analysis has identified nonmusclemyosin
as a component of the complex of proteins associated with the
NMDAR.48
At the synapse, NMDAR-effected postsynaptic calcium rise
activates CaMKII, which acts on downstream molecules, such
as cofilin, influencing actin dynamics that regulate activity-
dependent changes in synaptic strength.49 This pathway seems
operative also in podocytes, where actin reorganization after
NMDAR antagonists appears secondary to reduced phosphor-
ylation of CaMKII and cofilin, likely consequent to reduced
calcium entry as a result of closure of the NMDAR channel. It
Figure 8. Effects of ketamine administration during general an-
esthesia. The graph illustrates the change after anesthesia (H1/
H0) of the UAlb/UCreat values (mg/mmol) in patients who received
ketamine (ketamine) compared with those who did not (ket-
amine). The horizontal lines inside the boxes represent median
values, whereas bottom and top edges of the boxes represent the
25th and 75th percentiles and bottom and top whiskers reach the
10th and 90th percentiles, respectively.
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was shown that the very same pathway plays an important role
in dendritic spine remodeling and specifically requires
NMDAR, because analogue experiments performed onAMPA
receptors do not have the same effects.50
The specificity of effects caused by NMDAR blockers and
the similarity of events occurring in podocytes and neurons
seem further proved by their reversibility after addition of the
specific agonist NMDA and by the reboundNMDAR increase.
This NMDAR increase is so rapid that it can be achieved only
by trafficking of the receptor itself along the cytoskeleton; at
least in neurons, actin remodeling is thought to serve exactly to
this purpose.51
Together with these features, podocytes specifically dis-
played disappearance of nephrin from podocyte processes, a
variation that prompted our subsequent experiments on iso-
lated glomeruli and in vivo. Changes in nephrin expression
have been shown to accompany or even precedemost forms of
experimental and human proteinuric diseases,52 and, indeed,
nephrin changes were the only podocyte alterations accompa-
nying the increased albuminuria in norketamine-treated ani-
mals. Although the extremely low dosage and duration of nor-
ketamine treatment in vivo guarantee the absence of major
neurologic consequences and stand for the action of norket-
amine on the glomerulus, the experiments performed on iso-
lated glomeruli are those providing evidence of the direct effect
of NMDAR antagonists on glomerular filtration. The useful-
ness of the method has been repeatedly proved in different
experimental settings.53,54 In this work it even confirmed the
predicted stronger, less reversible action of MK-801.
In summary, our data seem to provide evidence in favor of
the hypothesis that glutamatergic signaling driven by podo-
cytes is relevant to the integrity of the filtering barrier, because
its derangements are accompanied by podocyte changes and
increased albuminuria. Analogue results have been shown in
other cells, such as osteoblasts, in which NMDAR antagonists
inhibit differentiation and matrix mineralization,55 leading us
to speculate that highly specialized cells, requiring continuous
modulation of their activity, rely on the spatial and temporal
precision of glutamate to finely tune theirmost regulated func-
tions. Although preliminary and conducted on a limited num-
ber of cases, the human study adds to our observations an
initial evidence of the potential importance of this system in
the clinical setting and certainly suggests the usefulness of fur-
ther investigation in this direction.
CONCISE METHODS
Animal Models
All rodent protocols strictly adhered to the Public Health Service Pol-
icy on Humane Care and Use of Laboratory Animals, and were ap-
proved by the Milan University Institutional Care and Ethical Treat-
ment Committee. All animals were housed on a 12-h light/dark cycle,
and allowed free access to food and water.
Balb/c mice and homozygous H-2Kb-tsA58 transgenic mice were
acquired from Charles River Laboratories Italia (Calco, Lecco, Italy).
Sprague-Dawley rats were fromHarlan (S. Pietro al Natisone, Udine,
Italy).
Rab3A KO mice (Rab3A-KO; Rab3A/; B6;129S-Rab3atm1Sud/J)
and the appropriate WT (Rab3A-WT, Rab3A/; B6129SF2/J) were
fromJacksonLaboratory (BarHarbor,ME).Backcrosseswere generated,
and the offspring were genotyped using the following primers: KO for-
wardGCCGCACGGAGAGGAAGAATAGG;KO reverse CGGTGG
GCT CTA TGG CTT CTG A (amplification product 900 bp); WT for-
ward GCGCAACCCAGGTCCACACA;WT reverse ACGCACAAG
CCT CCC GCA AG (amplification product 210 bp). Genotyping of the
H-2Kb-tsA58 transgenic was conducted by the following primers: for-
ward GTC ACA CCA CAG AAG TAA GGT TCC; reverse AGC GCT
TGTGTCGCCATTGTA TTC.
Podocyte Cell Cultures
For primary cultures, kidneys were taken from7- to 10-d-old rodents,
as described previously.17 Briefly, glomeruli were isolated by sieving,
then seeded in culture flasks (Corning, Sigma-Aldrich, Milan, Italy)
precoated with collagen type IV (Sigma-Aldrich) at 37°C in 5% CO2
atmosphere. After 1 wk, first-passage podocytes were separated from
glomeruli by an additional sieving through the 36-mmesh. Second-
passage podocytes were seeded on flasks and thermanox coverslips
(Nunc, VWR Int., Milan, Italy). Cell characterization was performed
by morphology and immunofluorescence, using podocyte (nephrin,
podocin), epithelial (cytokeratins), smooth muscle (-smooth mus-
cle actin), and endothelial cell (CD31) markers.
For the conditionally immortalized cell line, we followed with mi-
nor modifications the procedure originally published by Mundel et
al.19 Briefly, glomeruli were isolated from kidneys of adult (10-wk-
old) transgenicH-2Kb-tsA58mice by the same procedure as described
already and grown first in standard medium at 37°C. Second-passage
cells were replated and propagated at 33°C in medium containing 20
U/ml recombinant mouse -IFN (Sigma-Aldrich). Limiting dilution
(10.0, 1.0, and 0.1 cells/vial) of these cells was followed by character-
ization, and only five clones expressingWT1 andnephrin on90%of
cells were selected and propagated. For initiation of differentiation,
cells were thermo-shifted to 37°C andmaintained inmediumwithout
-IFN.
Spontaneous and Stimulated Glutamate Release Assay
As described previously,17,56 glutamate release was detected by an en-
zymatic assay based on the following reaction that occurs in the pres-
ence of glutamate dehydrogenase: Glutamate  NAD  H2O7
ketoglutarate2NADHNAD4H (all reagents from Sigma-
Aldrich).
In brief, podocytes were plated and grown to semiconfluence. Be-
fore measurements, cells were thoroughly washed and incubated for
1 h at 37°C inDMEM-F12 buffer containing 1mMMgCl2 and 20mM
HEPES. The medium was further supplemented with glutamate de-
hydrogenase (60 U/ml) and NAD (1 mM) and incubated for 5 min.
Then, either medium (to evaluate spontaneous exocytosis) or 2.5 nM
-LTX was added, and spectrophotometric increase of OD due to
increase of NADH was monitored at 340 nm every 10 min. Results
were expressed as percentage variations from the baseline.
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In Vivo Monitoring of Recycling Vesicles
The styryl dye FM1–43 (Invitrogen, S. Giuliano Milanese, Italy),
which has no fluorescence properties in aqueous solution but be-
comes fluorescent on membrane binding, allows the labeling of recy-
cling vesicles that is easily detectable by fluorescencemicroscopy.57 In
our experiments, the dye was added to the cell medium at a 2-M
concentration. Cells were maintained under observation for the
whole duration of the experiment by the AxioVert 40 microscope
(Zeiss, Arese, Mi, Italy) equipped for immunofluorescence. Dye flu-
orescence (wave length excitation 479; emission 598) of cells incu-
bated inmedium and after addition of 2.5 nM-LTXwas recorded by
a digital videocamera (AxioCam MRC; Zeiss), with acquisition pa-
rameters settled by the “live” module of the software AxioVision
(Zeiss).
Animal Studies
See supplemental material.
Immunofluorescence Studies
See supplemental material.
Immunogold Electron Microscopy
An indirect immunogold labeling procedure was performed on ultra-
thin frozen kidney sections, as described previously.16 Briefly, after
blocking, the material was incubated with the primary antibody fol-
lowed by the proper secondary gold-conjugated goat anti-rabbit or
goat anti-mouse IgG (HL) 12 nm (Jackson ImmunoResearch Eu-
rope, Suffolk, UK).
Specificity of antibody labeling was demonstrated by the lack of
staining after substituting proper control Igs (Invitrogen) for the pri-
mary antibody.
Western Blot
See supplemental material.
Convective Glomerular PAlb Test
As described previously,58 Sprague-Dawley rat glomeruli were iso-
lated by sieving from the renal cortex in isotonic PBS, and 5 g/dl BSA
was added to the medium as an oncotic agent. Glomeruli were video-
taped through an inverted microscope before and after the medium
exchange from 5 to 1 g/dl BSA, used to create an oncotic gradient
across the basementmembrane, that resulted in ameasurable glomer-
ular volume change [	V (Vfinal Vinitial)/Vinitial], which could be
measured off-line by a video-based image analysis software (Sigma
Scan Pro) that determines the area of the glomerulus in the two-
dimensional space and calculates the volume by a mathematical for-
mula.
Because there is a direct relationship between the increase in glo-
merular volume (	V) and the oncotic gradient (	
) applied across
the capillary wall, this principle was applied to calculate alb, using
the ratio of	Vof experimental to	Vof control glomeruli in response
to identical oncotic gradients: alb  	Vexperimental/	Vcontrol. Con-
vectional PAlb was therefore defined as (1  alb) to describe the
movement of albumin consequent to water flow. When alb is 0,
albuminmoves at the same rate aswater andPAlb is 1.0. Alternatively,
whenalb is 1.0, albumin cannot cross themembrane with water and
PAlb is 0. It is assumed that the experiment is positive to PAlb test
when values are0.5.
NMDAR Blockade
The glutamate receptor antagonist norketamine hydrochloride (Toc-
ris Bioscience, Bristol, UK) was diluted into the cell medium at the
concentration of 50  for 30 min, whereas the more potent antag-
onist MK801 (Tocris Bioscience) was added at a concentration of
10M. In some experiments, the agonist NMDA (Tocris Bioscience)
was added at a concentration of 50 M for 15 min.
Human Study
The human study design was in accordance to the Declaration of Hel-
sinki. After informed consent to the study, consecutive patients sched-
uled for gynecologic surgerywere prospectively includedduring a period
of 2 mo. All patients were orally premedicated with 1.5 mg/kg hy-
droxyzine, then randomly assigned to receive intraoperative low-dosage
chlorhydrate ketamine (intravenous bolus of 0.15 mg/kg; ketamine
group) for preemptive analgesic effect or nothing (ketamine group),
during standardized induction of general anesthesia (0.3 g/kg sufenta-
nyl, 2 to 3 mg/kg propofol, and 0.5 mg/kg atracrium, followed bymain-
tenance with 6 to 9 mg/kg propofol or 1.0 to 1.5% isoflurane in 50%
N2O/40%O2). Both protocols were routinely in use.
Inclusion criteria were age (20 to 60 yr) and admittance for celio-
scopic or transvaginal surgery. Patients presenting preexisting stages 3
through 5 chronic kidney disease (estimated GFR using the four-
variable Modification of Diet in Renal Disease [MDRD] study equa-
tion60ml/min per 1.73m2), baselineUAlb/UCreat3.39mg/mmol,
diabetes, renin-angiotensin-aldosterone blocker medication, or pre-
existing allergy to ketamine were not included in the study.
Exclusion criteria were the use of hydroxyethyl starch and per-
procedure hemodynamic instability (defined by fluid loading1000
ml crystalloid/30 min and/or use of vasopressors). Data included pa-
tients’ age and body mass index. Surgical route, type and volume of
fluid infusion, drugs used for anesthesia maintenance, and antibiotic
prophylaxis regimen were additionally collected. Noninvasive mean
arterial pressure was measured before (H0) and 1 h after (H1) ket-
amine administration. UAlb (immunonephelometry, Dade Behring
BNII) and UCreat (colorimetric Jaffe´ method, Beckman CX) were
measured on urine samples collected by urinary catheterization at H0
and H1, before any postoperative analgesic medication was given.
Primary objective of this pilot study was to compare UAlb/UCreat
difference betweenH0 andH1 in ketamine and ketamine groups.
Descriptive analyses were performed using median values (25th to
75th percentiles) for continuous variables and percentages for cate-
gorical variables. Values were compared with Mann-Whitney U test
or Fisher exact test, as appropriate.
ACKNOWLEDGMENTS
We thank Guido Brusini for technical assistance and Vincent Comp-
ere, MD, PhD, and Sophie Claeyssens, MD, for contribution to the
human study.
BASIC RESEARCH www.jasn.org
1938 Journal of the American Society of Nephrology J Am Soc Nephrol 20: 1929–1940, 2009
DISCLOSURES
None.
REFERENCES
1. Tryggvason K, Patrakka J, Wartiovaara J: Hereditary proteinuria syn-
dromes and mechanisms of proteinuria. N Engl J Med 354: 1387–
1401, 2006
2. Putaala H, Soininen R, Kilpelainen P, Wartiovaara J, Tryggvason K: The
murine nephrin gene is specifically expressed in kidney, brain and
pancreas: Inactivation of the gene leads to massive proteinuria and
neonatal death. Hum Mol Genet 10: 1–8, 2001
3. Donoviel DB, Freed DD, Vogel H, Potter DG, Hawkins E, Barrish JP,
Mathur BN, Turner CA, Geske R, Montgomery CA, Starbuck M, Brandt
M, Gupta A, Ramirez-Solis R, Zambrowicz BP, Powell DR: Proteinuria
and perinatal lethality in mice lacking NEPH1, a novel protein with
homology to NEPHRIN. Mol Cell Biol 21: 4829–4836, 2001
4. Ciani L, Patel A, Allen ND, ffrench-Constant C: Mice lacking the giant
protocadherin mFAT1 exhibit renal slit junction abnormalities and a
partially penetrant cyclopia and anophthalmia phenotype. Mol Cell
Biol 23: 3575–3582, 2003
5. Roselli S, Heidet L, Sich M, Henger A, Kretzler M, Gubler MC, Antig-
nac C: Early glomerular filtration defect and severe renal disease in
podocin-deficient mice. Mol Cell Biol 24: 550–560, 2004
6. Shih NY, Li J, Karpitskii V, Nguyen A, Dustin ML, Kanagawa O, Miner
JH, Shaw AS: Congenital nephrotic syndrome in mice lacking CD2-
associated protein. Science 286: 312–315, 1999
7. Kos CH, Le TC, Sinha S, Henderson JM, Kim SH, Sugimoto H,
Kalluri R, Gerszten RE, Pollak MR: Mice deficient in alpha-actinin-4
have severe glomerular disease. J Clin Invest 111: 1683–1690,
2003
8. Reiser J, Polu KR, Mo¨ller CC, Kenlan P, Altintas MM, Wei C, Faul C,
Herbert S, Villegas I, Avila-Casado C, McGee M, Sugimoto H, Brown
D, Kalluri R, Mundel P, Smith PL, Clapham DE, Pollak MR: TRPC6 is a
glomerular slit diaphragm-associated channel required for normal re-
nal function. Nat Genet 37: 739–744, 2005
9. Kobayashi N, Gao SY, Chen J, Saito K, Miyawaki K, Li CY, Pan L, Saito
S, Terashita T, Matsuda S: Process formation of the renal glomerular
podocyte: Is there common molecular machinery for processes of
podocytes and neurons? Anat Sci Int 79: 1–10, 2004
10. Gerke P, Benzing T, Ho¨hne M, Kispert A, Frotscher M, Walz G, Kretz
O: Neuronal expression and interaction with the synaptic protein
CASK suggest a role for Neph1 and Neph2 in synaptogenesis.
J Comp Neurol 498: 466–475, 2006
11. Beltran PJ, Bixby JL, Masters BA: Expression of PTPRO during mouse
development suggests involvement in axonogenesis and differentia-
tion of NT-3 and NGF-dependent neurons. J Comp Neurol 456:
384–395, 2003
12. Gloy J, Reitinger S, Fischer KG, Schreiber R, Boucherot A, Kunzelmann
K, Mundel P, Pavenstadt H: Amino acid transport in podocytes. Am J
Physiol Renal Physiol 278: F999–F1005, 2000
13. Mundel P, Heid HW, Mundel TM, Kruger M, Reiser J, Kritz W: Synap-
topodin: An actin-associated protein in telencephalic dendrites and
renal podocytes. J Cell Biol 139: 193–204, 1997
14. Peitsch WK, Hofmann I, Endlich N, Pratzel S, Kuhn C, Spring H, Grone
HJ, Kriz W, Franke WW: Cell biological and biochemical characteriza-
tion of drebrin complexes in mesangial cells and podocytes of renal
glomeruli. J Am Soc Nephrol 14: 1452–1463, 2003
15. Cohen CD, Doran PP, Blattner SM, Merkle M, Wang GQ, Schmid H,
Mathieson PW, Saleem MA, Henger A, Rastaldi MP, Kretzler M:
Sam68-like mammalian protein 2, identified by digital differential
display as expressed by podocytes, is induced in proteinuria and
involved in splice site selection of vascular endothelial growth factor.
J Am Soc Nephrol 16: 1958–1965, 2005
16. Rastaldi MP, Armelloni S, Berra S, Li M, Pesaresi M, Poczewski H,
Langer B, Kerjaschki D, Henger A, Blattner SM, Kretzler M, Wanke R,
D’Amico G: Glomerular podocytes possess the synaptic vesicle mol-
ecule Rab3A and its specific effector rabphilin-3a. Am J Pathol 163:
889–899, 2003
17. Rastaldi MP, Armelloni S, Berra S, Calvaresi N, Corbelli A, Giardino LA,
Li M, Wang GQ, Fornasieri A, Villa A, Heikkila E, Soliymani R, Bouch-
erot A, Cohen CD, Kretzler M, Nitsche A, Ripamonti M, Malgaroli A,
Pesaresi M, Forloni GL, Schlo¨ndorff D, Holthofer H, D’Amico G: Glo-
merular podocytes contain neuron-like functional synaptic vesicles.
FASEB J 20: 976–978, 2006
18. Stettler O, Moya KL, Zahraoui A, Tavitian B: Developmental changes
in the localization of the synaptic vesicle protein rab3A in rat brain.
Neuroscience 62: 587–600, 1994
19. Mundel P, Reiser J, Zu´n˜iga Mejı´a Borja A, Pavensta¨dt H, Davidson GR,
Kriz W, Zeller R: Rearrangements of the cytoskeleton and cell contacts
induce process formation during differentiation of conditionally im-
mortalized mouse podocyte cell lines. Exp Cell Res 236: 248–258,
1997
20. Sara Y, Virmani T, Dea`k F, Liu X, Kavalali ET: An isolated pool of
vesicles recycles at rest and drives spontaneous neurotransmission.
Neuron 45: 563–573, 2005
21. Saviane C, Silver RA: Fast vesicle reloading and a large pool sustain
high bandwidth transmission at a central synapse. Nature 439: 983–
987, 2006
22. Su¨dhof TC: Alpha-latrotoxin and its receptors: Neurexins and CIRL/
latrophilins. Annu Rev Neurosci 24: 933–962, 2001
23. Baldini G, Martelli AM, Tabellini G, Horn C, Machaca K, Narducci P,
Baldini G: Rabphilin localizes with the cell actin cytoskeleton and
stimulates association of granules with F-actin cross-linked by alpha-
actinin. J Biol Chem 280: 34974–34984, 2005
24. Ceccaldi PE, Grohovaz F, Benfenati F, Chieregatti E, Greengard P,
Valtorta F: Dephosphorylated synapsin I anchors synaptic vesicles to
actin cytoskeleton: An analysis by videomicroscopy. J Cell Biol 128:
905–912, 1995
25. Rao A, Craig AM: Activity regulates the synaptic localization of the
NMDA receptor in hippocampal neurons. Neuron 19: 801–812, 1997
26. Cingolani LA, Goda Y: Actin in action: The interplay between the actin
cytoskeleton and synaptic efficacy. Nat Rev Neurosci 9: 344–356,
2008
27. Xu Q, Ming Z, Dart AM, Du XJ: Optimizing dosage of ketamine and
xylazine in murine echocardiography. Clin Exp Pharmacol Physiol 34:
499–507, 2007
28. Galici R, Boggs JD, Miller KL, Bonaventure P, Atack JR: Effects of
SB-269970, a 5-HT7 receptor antagonist, in mouse models predic-
tive of antipsychotic-like activity. Behav Pharmacol 19: 153–159,
2008
29. Flavell SW, Greenberg ME: Signaling mechanisms linking neuronal
activity to gene expression and plasticity of the nervous system. Annu
Rev Neurosci 31: 563–590, 2008
30. Genever PG, Skerry TM: Regulation of spontaneous glutamate release
activity in osteoblastic cells and its role in differentiation and survival:
Evidence for intrinsic glutamatergic signaling in bone. FASEB J 15:
1586–1588, 2001
31. Moriyama Y, Hayashi M: Glutamate-mediated signaling in the islets of
Langerhans: A thread entangled. Trends Pharmacol Sci 24: 511–517,
2003
32. Hitchcock IS, Skerry TM, Howard MR, Genever PG: NMDA receptor-
mediated regulation of human megakaryocytopoiesis. Blood 102:
1254–1259, 2003
33. Schlu¨ter OM, Basu J, Su¨dhof TC, Rosenmund C: Rab3 superprimes
synaptic vesicles for release: Implications for short-term synaptic plas-
ticity. J Neurosci 26: 1239–1246, 2006
34. Miralles F, Serup P, Cluzeaud F, Vandewalle A, Czernichow P, Scharf-
BASIC RESEARCHwww.jasn.org
J Am Soc Nephrol 20: 1929–1940, 2009 Neuron-Like Podocyte Signaling 1939
mann R: Characterization of beta cells developed in vitro from rat
embryonic pancreatic epithelium. Dev Dyn 214: 116–126, 1999
35. Geppert M, Bolshakov VY, Siegelbaum SA, Takei K, De Camilli P,
Hammer RE, Su¨dhof TC: The role of Rab3A in neurotransmitter re-
lease. Nature 369: 493–497, 1994
36. Leenders AG, Lopes da Silva FH, Ghijsen WE, Verhage M: Rab3a is
involved in transport of synaptic vesicles to the active zone in mouse
brain nerve terminals. Mol Biol Cell 12: 3095–3102, 2001
37. Wang X, Thiagarajan R, Wang Q, Tewolde T, Rich MM, Engisch KL:
Regulation of quantal shape by Rab3A: Evidence for a fusion pore-
dependent mechanism. J Physiol 586: 3949–3962, 2008
38. Yang S, Farias M, Kapfhamer D, Tobias J, Grant G, Abel T, Bucan M:
Biochemical, molecular and behavioral phenotypes of Rab3A muta-
tions in the mouse. Genes Brain Behav 6: 77–96, 2007
39. Ba¨hler M, Greengard P: Synapsin I bundles F-actin in a phosphoryla-
tion-dependent manner. Nature 326: 704–707, 1987
40. Faul C, Asanuma K, Yanagida-Asanuma E, Kim K, Mundel P: Actin up:
Regulation of podocyte structure and function by components of the
actin cytoskeleton. Trends Cell Biol 17: 428–437, 2007
41. Wyszynski M, Lin J, Rao A, Nigh E, Beggs AH, Craig AM, Sheng M:
Competitive binding of alpha-actinin and calmodulin to the NMDA
receptor. Nature 385: 439–442, 1997
42. Wechsler A, Teichberg VI: Brain spectrin binding to the NMDA recep-
tor is regulated by phosphorylation, calcium and calmodulin. EMBO J
17: 3931–3939, 1998
43. Star EN, Kwiatkowski DJ, Murthy VN: Rapid turnover of actin in den-
dritic spines and its regulation by activity. Nat Neurosci 5: 239–246,
2002
44. Rosenmund C, Westbrook GL: Rundown of N-methyl-D-aspartate
channels during whole-cell recording in rat hippocampal neurons:
Role of Ca2 and ATP. J Physiol 470: 705–729, 1993
45. Sattler R, Xiong Z, Lu WY, MacDonald JF, Tymianski M: Distinct roles
of synaptic and extrasynaptic NMDAR in excitotoxicity. J Neurosci 20:
22–33, 2000
46. Ghiggeri GM, Caridi G, Magrini U, Sessa A, Savoia A, Seri M, Pecci A,
Romagnoli R, Gangarossa S, Noris P, Sartore S, Necchi V, Ravazzolo R,
Balduini CL: Genetics, clinical and pathological features of glomeru-
lonephritis associated with mutations of nonmuscle myosin IIA (Fecht-
ner syndrome). Am J Kidney Dis 41: 95–104, 2003
47. Fifkova E, Morales M: Calcium-regulated contractile and cytoskeletal
proteins in dendritic spines may control synaptic plasticity. Ann N Y
Acad Sci 568: 131–137, 1989
48. Husi H, Ward MA, Choudhary JS, Blackstock WP, Grant SG: Proteomic
analysis of NMDA receptor-adhesion protein signaling complexes.
Nat Neurosci 3: 661–669, 2000
49. Bliss TV, Collingridge GL: A synaptic model of memory: Longterm
potentiation in the hippocampus. Nature 361: 31–39, 1993
50. Thalhammer A, Rudhard Y, Tigaret CM, Volynski KE, Rusakov DA,
Schoepfer R: CaMKII translocation requires local NMDA receptor-
mediated Ca2 signaling. EMBO J 25: 5873–5883, 2006
51. Fujisawa S, Shirao T, Aoki C: In vivo, competitive blockade of N-
methyl-D-aspartate receptors induces rapid changes in filamentous
actin and drebrin A distributions within dendritic spines of adult rat
cortex. Neuroscience 140: 1177–1187, 2006
52. Holtho¨fer H: Molecular architecture of the glomerular slit diaphragm:
Lessons learnt for a better understanding of disease pathogenesis.
Nephrol Dial Transplant 22: 2124–2128, 2007
53. Candiano G, Musante L, Carraro M, Faccini L, Campanacci L, Zennaro
C, Artero M, Ginevri F, Perfumo F, Gusmano R, Ghiggeri GM: Apoli-
poproteins prevent glomerular albumin permeability induced in vitro
by serum from patients with focal segmental glomerulosclerosis. J Am
Soc Nephrol 12: 143–150, 2001
54. Candido R, Carraro M, Fior F, Artero ML, Zennaro C, Burrell LM, Davis
BJ, Cattin MR, Bardelli M, Faccini L, Carretta R, Fabris B: Glomerular
permeability defect in hypertension is dependent on renin angiotensin
system activation. Am J Hypertens 18: 844–850, 2005
55. Spencer GJ, McGrath CJ, Genever PG: Current perspectives on
NMDA-type glutamate signaling in bone. Int J Biochem Cell Biol 39:
1089–1104, 2007
56. Bezzi P, Carmignoto G, Pasti L, Vesce S, Rossi D, Rizzini BL, Pozzan T,
Volterra A: Prostaglandins stimulate calcium-dependent glutamate
release in astrocytes. Nature 391: 281–285, 1998
57. Cousin MA, Robinson PJ: Mechanisms of synaptic vesicle recycling
illuminated by fluorescent dyes. J Neurochem 73: 2227–2239, 1999
58. Savin VJ, Sharma R, Lovell HB, Welling DJ: Measurement of albumin
reflection coefficient with isolated rat glomeruli. J Am Soc Nephrol 3:
1260–1269, 1992
See related editorial, “Signaling at the Slit: Podocytes Chat by Synaptic Trans-
mission,” on pages 1862–1864.
Supplemental information for this article is available online at http://www.
jasn.org/.
BASIC RESEARCH www.jasn.org
1940 Journal of the American Society of Nephrology J Am Soc Nephrol 20: 1929–1940, 2009
